| 2.2539 -0.076 (-3.27%) | 01-09 13:02 | |||||||||||||
|
|
| Short term |  |
|||
| Mid term |  |
|||
| Targets | 6-month : | 2.87 | 1-year : | 3.22 |
| Resists | First : | 2.45 | Second : | 2.76 |
| Pivot price | 2.45 |
|||
| Supports | First : | 1.96 | Second : | 1.63 |
| MAs | MA(5) : | 2.37 |
MA(20) : | 2.36  |
| MA(100) : | 2.7 |
MA(250) : | 2.68 |
|
| MACD | MACD : | 0 |
Signal : | 0 |
| %K %D | K(14,3) : | 36.8 |
D(3) : | 47.6 |
| RSI | RSI(14): 43.8 |
|||
| 52-week | High : | 6.01 | Low : | 1.58 |
Price has closed below its short-term moving average. Short-term moving average is currently above mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and NEUTRAL in mid-long term.[ NRXP ] has closed above bottom band by 18.1%. Bollinger Bands are 19.2% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.
| If tomorrow: | Open lower | Open higher |
| High: | 2.45 - 2.47 | 2.47 - 2.48 |
| Low: | 2.25 - 2.27 | 2.27 - 2.28 |
| Close: | 2.3 - 2.33 | 2.33 - 2.35 |
NRX Pharmaceuticals, Inc., a clinical-stage pharmaceutical company, develops novel therapeutics for the treatment of central nervous system disorders and life-threatening pulmonary diseases. Its products include ZYESAMI, an investigational drug that has completed a Phase IIb/III clinical study for COVID-19 related respiratory failure; and NRX-100 and NRX-101 oral therapeutics for the treatment of bipolar depression in patients with acute suicidal behavior/ideation and sub-acute suicidal ideation and behavior. The company was founded in 2015 and is based in Wilmington, Delaware.
Mon, 05 Jan 2026
NRx Pharmaceuticals (Nasdaq:NRXP) and neurocare Group AG - GlobeNewswire
Mon, 05 Jan 2026
NRx Pharmaceuticals (NASDAQ: NRXP) Partners With neurocare Group AG To Build Nationwide Neuroplastic Care Network - The Globe and Mail
Thu, 18 Dec 2025
NRx Pharmaceuticals Completes Repayment of $5.4 Million Debt, Positioning Company for Growth in 2026 - Quiver Quantitative
Thu, 18 Dec 2025
NRx Pharmaceuticals (Nasdaq:NRXP) announces elimination of all balance sheet debt following equity conversion - GlobeNewswire
Tue, 16 Dec 2025
HC Wainwright & Co. Reiterates NRx Pharmaceuticals (NRXP) Buy Recommendation - Nasdaq
Wed, 03 Dec 2025
NRx Pharmaceuticals (NRXP) Amends IND to Advance NRX-101 With TMS for Depression Treatment - Yahoo Finance
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Underperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Underperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Outperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 0 (M) |
| Shares Float | 30 (M) |
| Held by Insiders | 2.072e+007 (%) |
| Held by Institutions | 9.7 (%) |
| Shares Short | 1,360 (K) |
| Shares Short P.Month | 0 (K) |
| EPS | -1.52e+007 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 0 |
| Profit Margin | 0 % |
| Operating Margin | -1 % |
| Return on Assets (ttm) | 701.6 % |
| Return on Equity (ttm) | -97.9 % |
| Qtrly Rev. Growth | 242000 % |
| Gross Profit (p.s.) | 0 |
| Sales Per Share | 0 |
| EBITDA (p.s.) | 75520.8 |
| Qtrly Earnings Growth | -2.4 % |
| Operating Cash Flow | 0 (M) |
| Levered Free Cash Flow | -13 (M) |
| PE Ratio | -0.01 |
| PEG Ratio | 0 |
| Price to Book value | 0 |
| Price to Sales | 0 |
| Price to Cash Flow | -4.69 |
| Dividend | 0 |
| Forward Dividend | 1.74e+006 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|